Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
03 2022
Historique:
received: 07 09 2021
revised: 20 12 2021
accepted: 10 01 2022
pubmed: 18 1 2022
medline: 5 3 2022
entrez: 17 1 2022
Statut: ppublish

Résumé

The VEGF-A-induced functional impairment of the barrier formed by retinal endothelial cells (REC) can be prevented and even - at least temporarily - reverted by trapping the growth factor in a complex with a VEGF-binding protein or by inhibiting the activity of the VEGF receptor 2 (VEGFR2). In an approach to emulate the clinically relevant situation of constant exposure to effectors, we investigated (1) whether prolonged exposure to VEGF-A

Identifiants

pubmed: 35038456
pii: S0014-4835(22)00026-4
doi: 10.1016/j.exer.2022.108945
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Antibodies, Monoclonal, Humanized 0
Claudin-1 0
Claudin-5 0
Peptide Fragments 0
Vascular Endothelial Growth Factor A 0
vascular endothelial growth factor A (138-165) 0
brolucizumab XSZ53G39H5
Ranibizumab ZL1R02VT79

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108945

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Heidrun L Deissler (HL)

Department of Ophthalmology, Ulm University Medical Center, Ulm, Germany. Electronic address: heidrun.deissler@uniklinik-ulm.de.

Matus Rehak (M)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany; Department of Ophthalmology, Justus-Liebig-University Giessen, Giessen, Germany.

Catharina Busch (C)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Armin Wolf (A)

Department of Ophthalmology, Ulm University Medical Center, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH